Euclises is a drug discovery and development technology platform that offers novel pain and cancer medications. Their platform focuses on developing novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting, as well as develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform, enabling physicians to access advanced new molecules in combinations with both immune checkpoint and EGFR inhibitors to treat cancer.
Argonautic iSelect Special Situations Fund I SP (AISS)
View website